Alisa J Stephens-Shields1, J Quentin Clemens2, Thomas Jemielita3, John Farrar3, Siobhan Sutcliffe4, Xiaoling Hou5, J Richard Landis3. 1. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: alisaste@mail.med.upenn.edu. 2. Department of Urology, University of Michigan, Ann Arbor, Michigan. 3. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Surgery, Washington University, St. Louis, Missouri. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
PURPOSE: We examined symptom variability in men and women with urological chronic pelvic pain syndrome. We describe symptom fluctuations as related to early symptom regression and its effect on estimated 1-year symptom change. We also describe a method to quantify patient specific symptom variability. MATERIALS AND METHODS: Symptoms were assessed biweekly in 424 subjects with urological chronic pelvic pain syndrome during 1 year. To evaluate the impact of early symptom regression subjects were classified as improved, no change or worse according to the rate of change using 1) all data, 2) excluding week 0 and 3) excluding weeks 0 and 2. Patient specific, time varying variability was calculated at each interval using a sliding window approach. Patients were classified as high, medium or low variability at each time and ultimately as high or low variability overall based on the variability for the majority of contacts. RESULTS: Prior to excluding early weeks to adjust for early symptom regression 25% to 38% and 5% to 6% of patients were classified as improved and worse, respectively. After adjustment the percent of patients who were improved or worse ranged from 15% to 25% and 6% to 9%, respectively. High and low variability phenotypes were each identified in 25% to 30% of participants. CONCLUSIONS: Patients with urological chronic pelvic pain syndrome show symptom variability. At study enrollment patients had worse symptoms on average, resulting in a regression effect that influenced the estimated proportion of those who were improved or worse. Prospective studies should include a run-in period to account for regression to the mean and other causes of early symptom regression. Further, symptom variability may be quantified and used to characterize longitudinal symptom profiles of urological chronic pelvic pain syndrome.
PURPOSE: We examined symptom variability in men and women with urological chronic pelvic pain syndrome. We describe symptom fluctuations as related to early symptom regression and its effect on estimated 1-year symptom change. We also describe a method to quantify patient specific symptom variability. MATERIALS AND METHODS: Symptoms were assessed biweekly in 424 subjects with urological chronic pelvic pain syndrome during 1 year. To evaluate the impact of early symptom regression subjects were classified as improved, no change or worse according to the rate of change using 1) all data, 2) excluding week 0 and 3) excluding weeks 0 and 2. Patient specific, time varying variability was calculated at each interval using a sliding window approach. Patients were classified as high, medium or low variability at each time and ultimately as high or low variability overall based on the variability for the majority of contacts. RESULTS: Prior to excluding early weeks to adjust for early symptom regression 25% to 38% and 5% to 6% of patients were classified as improved and worse, respectively. After adjustment the percent of patients who were improved or worse ranged from 15% to 25% and 6% to 9%, respectively. High and low variability phenotypes were each identified in 25% to 30% of participants. CONCLUSIONS:Patients with urological chronic pelvic pain syndrome show symptom variability. At study enrollment patients had worse symptoms on average, resulting in a regression effect that influenced the estimated proportion of those who were improved or worse. Prospective studies should include a run-in period to account for regression to the mean and other causes of early symptom regression. Further, symptom variability may be quantified and used to characterize longitudinal symptom profiles of urological chronic pelvic pain syndrome.
Authors: Kathleen Joy Propert; Mary McNaughton-Collins; Benjamin E Leiby; Michael P O'Leary; John W Kusek; Mark S Litwin Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: J Quentin Clemens; Elizabeth A Calhoun; Mark S Litwin; Mary McNaughton-Collins; John W Kusek; Evelyn M Crowley; J Richard Landis Journal: Urology Date: 2009-10-02 Impact factor: 2.649
Authors: John T Farrar; Andrea B Troxel; Kevin Haynes; Ian Gilron; Robert D Kerns; Nathaniel P Katz; Bob A Rappaport; Michael C Rowbotham; Ann M Tierney; Dennis C Turk; Robert H Dworkin Journal: Pain Date: 2014-05-14 Impact factor: 6.961
Authors: J Quentin Clemens; Chris Mullins; John W Kusek; Ziya Kirkali; Emeran A Mayer; Larissa V Rodríguez; David J Klumpp; Anthony J Schaeffer; Karl J Kreder; Dedra Buchwald; Gerald L Andriole; M Scott Lucia; J Richard Landis; Daniel J Clauw Journal: BMC Urol Date: 2014-08-01 Impact factor: 2.264
Authors: J Richard Landis; David A Williams; M Scott Lucia; Daniel J Clauw; Bruce D Naliboff; Nancy A Robinson; Adrie van Bokhoven; Siobhan Sutcliffe; Anthony J Schaeffer; Larissa V Rodriguez; Emeran A Mayer; H Henry Lai; John N Krieger; Karl J Kreder; Niloofar Afari; Gerald L Andriole; Catherine S Bradley; James W Griffith; David J Klumpp; Barry A Hong; Susan K Lutgendorf; Dedra Buchwald; Claire C Yang; Sean Mackey; Michel A Pontari; Philip Hanno; John W Kusek; Chris Mullins; J Quentin Clemens Journal: BMC Urol Date: 2014-08-01 Impact factor: 2.264
Authors: Andrew Schrepf; Bruce Naliboff; David A Williams; Alisa J Stephens-Shields; J Richard Landis; Arpana Gupta; Emeran Mayer; Larissa V Rodriguez; Henry Lai; Yi Luo; Catherine Bradley; Karl Kreder; Susan K Lutgendorf Journal: Ann Behav Med Date: 2018-09-13
Authors: J Quentin Clemens; Alisa Stephens-Shields; Bruce D Naliboff; H Henry Lai; Larissa Rodriguez; John N Krieger; David A Williams; John W Kusek; J Richard Landis Journal: J Urol Date: 2018-01-04 Impact factor: 7.450
Authors: Bruce D Naliboff; Alisa J Stephens; H Henry Lai; James W Griffith; J Quentin Clemens; Susan Lutgendorf; Larissa V Rodriguez; Craig Newcomb; Siobhan Sutcliffe; Wensheng Guo; John W Kusek; J Richard Landis Journal: J Urol Date: 2017-05-18 Impact factor: 7.450
Authors: J Quentin Clemens; Jason J Kutch; Emeran A Mayer; Bruce D Naliboff; Larissa V Rodriguez; David J Klumpp; Anthony J Schaeffer; Karl J Kreder; Daniel J Clauw; Steven E Harte; Andrew D Schrepf; David A Williams; Gerald L Andriole; H Henry Lai; Dedra Buchwald; M Scott Lucia; Adrie van Bokhoven; Sean Mackey; Robert M Moldwin; Michel A Pontari; Alisa J Stephens-Shields; Chris Mullins; J Richard Landis Journal: Neurourol Urodyn Date: 2020-06-23 Impact factor: 2.696
Authors: Jason J Kutch; Jennifer S Labus; Richard E Harris; Katherine T Martucci; Melissa A Farmer; Sonja Fenske; Connor Fling; Eric Ichesco; Scott Peltier; Bogdan Petre; Wensheng Guo; Xiaoling Hou; Alisa J Stephens; Chris Mullins; Daniel J Clauw; Sean C Mackey; A Vania Apkarian; J Richard Landis; Emeran A Mayer Journal: Pain Date: 2017-06 Impact factor: 6.961
Authors: Tianlin Xu; H Henry Lai; Ratna Pakpahan; Joel Vetter; Gerald L Andriole; Catherine Bradley; Bruce D Naliboff; Graham A Colditz; Siobhan Sutcliffe Journal: Neurourol Urodyn Date: 2019-09-04 Impact factor: 2.367
Authors: Bruce D Naliboff; Andrew D Schrepf; Alisa J Stephens-Shields; J Quentin Clemens; Michael A Pontari; Jennifer Labus; Bayley J Taple; Larissa V Rodriguez; Eric Strachan; James W Griffith Journal: J Urol Date: 2021-02-04 Impact factor: 7.600
Authors: Steven E Harte; Andrew Schrepf; Robert Gallop; Grant H Kruger; Hing Hung Henry Lai; Siobhan Sutcliffe; Megan Halvorson; Eric Ichesco; Bruce D Naliboff; Niloofar Afari; Richard E Harris; John T Farrar; Frank Tu; John Richard Landis; Daniel J Clauw Journal: Pain Date: 2019-06 Impact factor: 7.926